Latest Investments News

Hubify has completed a strategic $250,000 placement at a striking 425% premium to fund its AI-first growth strategy, including a key partnership with HubLab to deliver AI-powered ICT and cybersecurity services.

Virgin Australia has reported robust first-half FY26 results, with underlying EBIT up 11.7% driven by strong leisure travel and transformation gains, despite inflationary pressures.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

PEXA Group Limited reported a 10% revenue increase and a 19% rise in EBITDA for the half-year ended December 2025, while announcing its strategic exit from the Digital Solutions segment with a significant loss.

PPK Group Limited has reported a remarkable turnaround with a $10.5 million profit for H1 2026, driven by a significant non-cash gain from its Li-S Energy investment and strategic portfolio adjustments.

Dateline Resources has acquired the Music Valley Heavy Rare Earths Project in California, backed by historical high-grade data, and invested US$1 million in Fermi Critical Minerals to boost exploration across the US. This move complements its existing gold and rare earth projects, positioning the company at the forefront of critical mineral supply chain security.

TPG Telecom reported a robust FY25 with strategic asset sales, a major network sharing deal, and a $3 billion capital return, underpinning strong financial and sustainability progress.

Auric Mining has exceeded its 2026 gold production budgets at the Munda Starter Pit, delivering strong early results that validate the economic potential of the larger Munda Main Pit.

SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

WT Financial Group has reported robust half-year results for H1 FY2026, marked by a 20.8% increase in underlying net profit after tax and a fully franked interim dividend. The company’s strategic pivot to a business-to-business advice model and its Investco joint venture underpin its growth trajectory.

Harvest Technology Group’s half-year report reveals a 50% revenue decline and a widening net loss, offset by a $6 million funding facility and strategic partnerships.